Literature DB >> 23713935

Binocular vision outcomes following surgery for long-standing large angle exodeviation.

Lindsay K Gill1, Kyle Arnoldi.   

Abstract

INTRODUCTION: One goal of pre-operative sensorimotor testing is to determine fusion potential. Potential for recovery of binocularity following surgical repair of strabismus is inversely correlated to duration of misalignment. The purpose of this study was to determine binocular vision outcomes in long-standing, large-angle, constant exotropia, when the pre-operative sensorimotor exam predicts poor sensory outcome.
METHODS: Patients with constant exotropia >35Δ, present for ≥20 years, and scheduled to undergo strabismus surgery were recruited. Subjects were sorted into 3 groups based on pre-operative sensorimotor results. Group A had evidence of fusion pre-operatively, Group B demonstrated suppression on all tests, and Group C demonstrated paradoxical diplopia on at least one test.
RESULTS: Twenty patients were included: 11 in Group A, 5 in Group B, and 4 in Group C. Binocular vision was regained following surgery by 100% in Group A, 80% in Group B, and 50% in group C.
CONCLUSION: Surgical realignment leads to improvements in binocular vision in most patients, even in the case of very long-standing, large, constant deviations. The presence of paradoxical diplopia or dense suppression pre-operatively does not preclude a good sensory outcome.

Entities:  

Mesh:

Year:  2013        PMID: 23713935     DOI: 10.3109/09273972.2013.786743

Source DB:  PubMed          Journal:  Strabismus        ISSN: 0927-3972


  2 in total

1.  The fast exodrift after the first surgical treatment of exotropia and its correlation with surgical outcome of second surgery.

Authors:  Won Jae Kim; Myung Mi Kim
Journal:  BMC Ophthalmol       Date:  2018-03-02       Impact factor: 2.209

Review 2.  Intermittent exotropia: Surgical treatment strategies.

Authors:  Jai Aditya Kelkar; Santhan Gopal; Rachana B Shah; Aditya S Kelkar
Journal:  Indian J Ophthalmol       Date:  2015-07       Impact factor: 1.848

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.